A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

Inclusion Criteria:

* Age ≥ 18 years.
* Willing and able to give written informed consent.
* Diagnosis of primary AML or AML secondary to myelodysplastic syndrome (MDS) according to World Health Organization classification.
* Relapsed after or refractory to first-line AML therapy.
* Positive for FLT3 mutation in bone marrow or whole blood.
* Eastern Cooperative Oncology Group performance status ≤ 2 with no deterioration during screening period.
* Adequate hepatic and renal function.
* Recovery from non-hematologic AEs associated with prior therapy to baseline CTCAE v5 Grade 0 or 1, except for AEs not considered a safety risk (eg, alopecia or vitiligo).
* Able to take oral medication with no medical conditions that prevent swallowing and absorbing oral medications.
* Willing to comply with all protocol-required visits, assessments, and procedures.

Exclusion Criteria:

* Diagnosis of AML secondary to prior chemotherapy or other neoplasms (except for MDS).
* Diagnosis of acute promyelocytic leukemia or BCR-ABL-positive leukemia (chronic myeologenous leukemia in blast crisis).
* Clinically active central nervous system leukemia.
* Second or later hematologic relapse or prior salvage therapy for refractory disease.
* For participants being considered for ERAS-007+gilteritinib treatment: prior therapy with ERK inhibitor.
* For participants being considered for ERAS-601+gilteritinib treatment: prior therapy with SHP2 inhibitor.
* Anticancer therapy ≤14 days prior to first dose (except hydroxyurea given for controlling blast count), or ≤5 half-lives prior to first dose, whichever is shorter.
* Palliative radiation ≤7 days prior to first dose.
* Major surgery within 28 days of enrollment.
* Contraindication to gilteritinib use as per local label.
* Known hypersensitivity to any of the components of ERAS-007 or ERAS-601.
* Clinically active infection, requiring systemic therapy.
* Impaired cardiovascular function or clinically significant cardiovascular disease.
* History of thromboembolic or cerebrovascular events ≤6 months prior to first dose.
* History of other malignancy ≤3 years prior to first dose.
* History of retinal pigment epithelial detachment (RPED), central serous retinopathy, retinal vein occlusion (RVO), or risk factors to RPED or RVO.
* History of or clinically active interstitial lung disease (ILD), drug induced ILD, or radiation pneumonitis that required steroid treatment.
* Any evidence of severe or uncontrolled systemic disease or evidence of any other significant clinical disorder or laboratory finding that renders the participant inappropriate to participate in the study.
* Pregnant or breastfeeding women.